HK1068782A1 - Pharmaceutical composition of 2-(4-isobutylphenyl)propionic acid - Google Patents

Pharmaceutical composition of 2-(4-isobutylphenyl)propionic acid

Info

Publication number
HK1068782A1
HK1068782A1 HK05100493A HK05100493A HK1068782A1 HK 1068782 A1 HK1068782 A1 HK 1068782A1 HK 05100493 A HK05100493 A HK 05100493A HK 05100493 A HK05100493 A HK 05100493A HK 1068782 A1 HK1068782 A1 HK 1068782A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
ibuprofen
arginine
isobutylphenyl
propionic acid
Prior art date
Application number
HK05100493A
Other languages
English (en)
Inventor
Leo Pavliv
Original Assignee
Cumberland Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cumberland Pharmaceuticals Inc filed Critical Cumberland Pharmaceuticals Inc
Publication of HK1068782A1 publication Critical patent/HK1068782A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK05100493A 2001-11-02 2005-01-19 Pharmaceutical composition of 2-(4-isobutylphenyl)propionic acid HK1068782A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/042894 WO2003039532A1 (en) 2001-11-02 2001-11-02 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid

Publications (1)

Publication Number Publication Date
HK1068782A1 true HK1068782A1 (en) 2005-05-06

Family

ID=21742977

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100493A HK1068782A1 (en) 2001-11-02 2005-01-19 Pharmaceutical composition of 2-(4-isobutylphenyl)propionic acid

Country Status (13)

Country Link
EP (1) EP1439830B1 (ko)
JP (1) JP5185488B2 (ko)
KR (1) KR100851679B1 (ko)
CN (1) CN1302771C (ko)
AT (1) ATE306917T1 (ko)
AU (1) AU2002224475B2 (ko)
CA (1) CA2462452C (ko)
DE (1) DE60114249T2 (ko)
DK (1) DK1439830T3 (ko)
ES (1) ES2253326T3 (ko)
HK (1) HK1068782A1 (ko)
MX (1) MXPA04004024A (ko)
WO (1) WO2003039532A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132823A1 (en) * 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
KR101019201B1 (ko) 2008-01-30 2011-03-03 대화제약 주식회사 덱시부프로펜 알지닌염의 제조방법
PT3417708T (pt) 2009-03-12 2020-10-12 Cumberland Pharmaceuticals Inc Administração de ibuprofeno intravenoso
US8735452B2 (en) * 2009-07-15 2014-05-27 Cumberland Pharmaceuticals Inc. Treating patients with intravenous ibuprofen
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
MY174442A (en) * 2009-07-31 2020-04-18 Cumberland Pharmaceuticals Inc Treating critically ill patients with intravenous ibuprofen
MX2010004974A (es) 2010-05-04 2011-11-23 Senosiain S A De C V Lab Combinacion de un aine y un aminoacido.
WO2011144766A1 (es) 2010-05-18 2011-11-24 Spain Pharma, S.A. Composición farmacéutica de ibuprofeno para inyección
PL2635269T3 (pl) 2010-11-04 2019-11-29 Aft Pharmaceuticals Ltd Kompozycja złożona
CN102552117B (zh) * 2010-12-27 2014-07-09 成都天台山制药有限公司 一种含有布洛芬的注射剂及其制备方法
ES2422563B1 (es) * 2012-03-08 2014-06-10 Farmalider S.A. Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2014176449A1 (en) * 2013-04-25 2014-10-30 Rinsenergy LLC Oral rinse composition and method to deliver energy supplements
CN103720647A (zh) * 2013-12-16 2014-04-16 扬子江药业集团广州海瑞药业有限公司 一种右旋布洛芬注射液组合物
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
AU2017307313B2 (en) * 2016-08-02 2021-09-09 Ambah Ip Limited Stable ibuprofen injectable composition
CN110693822A (zh) * 2019-09-29 2020-01-17 山东罗欣药业集团股份有限公司 一种布洛芬注射液及制备方法
KR20210073905A (ko) 2019-12-11 2021-06-21 (주)휴온스 이부프로펜 및 아르기닌을 함유하는 안정성이 개선된 주사용 제제
US20230172877A1 (en) * 2020-03-11 2023-06-08 University Of Virginia Patent Foundation Metabolites released from apoptotic cells act as novel tissue messengers
KR102478284B1 (ko) 2020-10-28 2022-12-15 이희엽 덱시부프로펜 함유 주사용 액상 조성물
CN112957323B (zh) * 2021-03-29 2022-08-16 北京佳诚医药有限公司 一种右旋布洛芬注射液
KR20220166738A (ko) 2021-06-10 2022-12-19 (주)휴온스 이부프로펜, 아르기닌 및 염화나트륨을 함유하고, 불순물 저감을 통해 안정성이 개선된 희석 주사용 제제
AR127532A1 (es) * 2021-12-01 2024-02-07 Quim Luar S R L Composición farmacéutica que comprende ibuprofeno y arginina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6393718A (ja) * 1986-10-07 1988-04-25 Green Cross Corp:The 注射剤
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
IT1264857B1 (it) * 1993-06-21 1996-10-17 Zambon Spa Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico

Also Published As

Publication number Publication date
EP1439830A1 (en) 2004-07-28
DK1439830T3 (da) 2006-02-13
KR100851679B1 (ko) 2008-08-13
MXPA04004024A (es) 2004-10-29
CN1302771C (zh) 2007-03-07
AU2002224475B2 (en) 2008-01-17
CN1585635A (zh) 2005-02-23
DE60114249D1 (de) 2006-03-02
JP2005510510A (ja) 2005-04-21
WO2003039532A1 (en) 2003-05-15
DE60114249T2 (de) 2006-05-18
JP5185488B2 (ja) 2013-04-17
ATE306917T1 (de) 2005-11-15
ES2253326T3 (es) 2006-06-01
CA2462452C (en) 2006-07-04
CA2462452A1 (en) 2003-05-15
KR20040063913A (ko) 2004-07-14
EP1439830B1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
HK1068782A1 (en) Pharmaceutical composition of 2-(4-isobutylphenyl)propionic acid
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
MXPA03000510A (es) Sales estables de acido o-acetilsalicilico con aminoacidos basicos.
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
DOP2002000512A (es) Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
IL140848A (en) Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
NZ334961A (en) Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20023551L (no) Ibuprofen-inneholdende aktivt middel-preparat
IT1292130B1 (it) Processo per la preparazione dell'acido 1,4,7,10-tetraazaciclododecan -1,4,7-triacetico e suoi derivati
DE60313998D1 (de) Schmerzfreie injektions-zubereitungen von 2-arylpropionsäuresalzen
CA2245250A1 (fr) Derives d'acides benzofuranne-acryliques et leur utilisation comme modulateurs des recepteurs rxrs ou rars
CA2373962A1 (en) Immediate release medicinal compositions for oral use
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
WO2004093867A3 (en) Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
ES8305759A1 (es) "un procedimiento para la preparacion de 1-(1,3-bendodioxol-5-il)-2-pirrolidinona".
WO2003063858A3 (fr) Derives de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
HK1075006A1 (en) Use of spirolaxine for the preparation of a medicament treating type 2 insulin-resistant diabetes mellitus

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211101